Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of LuAA21004 in Major Depressive Disorder
jRCT2080221453Phase 3
- Sponsor
- Takeda
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing LuAA21004 with Placebo (2 arms).
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080221453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221453.